Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARG | Q86W56 | 10/20 | 0.47 |
| ▸ | RORC | P51449 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RORA | P35398 | 1/20 | 0.38 |
| ▸ | RORB | Q92753 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18763307 | 0.86 | RORC (0.47) | PARGRORCKMT2AHPGDMAPT | |
| SCHEMBL17335989 | 0.77 | PARG (0.41) | PARGRORCTSHRKMT2AHPGD | |
| SCHEMBL17335990 | 0.77 | SMN1; SMN2 (0.50) | PARGTSHRKMT2AHPGDMAPT | |
| SCHEMBL14927474 | 0.76 | RORA (0.45) | PARGRORCTSHRKMT2ARORA | |
| SCHEMBL10084682 | 0.74 | PARG (0.44) | PARGRORCTSHRHPGDRORA | |
| SCHEMBL19322789 | 0.72 | RORC (0.56) | PARGRORCHPGDMAPT | |
| SCHEMBL19669660 | 0.71 | PARG (0.51) | PARGRORCTSHRKMT2AMAPT | |
| SCHEMBL17347875 | 0.69 | ALDH1A1 (0.42) | PARGTSHRKMT2AHPGDTAS2R14 | |
| SCHEMBL17434571 | 0.65 | KDM4E (0.55) | PARGRORCTSHRKMT2AHPGD | |
| SCHEMBL12963549 | 0.64 | ALDH1A1 (0.51) | PARGTSHRKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114029-A1 | TREATMENT OF CHAGAS DISEASE | SYNGENE INTERNATIONAL LIMITED (IN) | 2017-04-27 | — | — | US | disclosed |
| US-20170114029-A1 | TREATMENT OF CHAGAS DISEASE | SYNGENE INTERNATIONAL LIMITED (IN) | 2017-04-27 | — | — | US | disclosed |
| WO-2015189595-A1 | TREATMENT OF CHAGAS DISEASE | UNIVERSITY OF DUNDEE (GB) | 2015-12-17 | — | — | WO | disclosed |
| WO-2015189595-A1 | TREATMENT OF CHAGAS DISEASE | UNIVERSITY OF DUNDEE (GB) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114029-A1 | TREATMENT OF CHAGAS DISEASE | CXCR4, CBR1, CHRM1 | PARG 4791/4885RORC 232/4885TSHR 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.